# Multi-cancer early detection (MCED) A single blood draw screening asymptomatic, average-risk individuals for signals of dozens of cancer types simultaneously, aiming to catch cancer before symptoms appear — distinct from treatment-matched companion diagnostics: GRAIL's Galleri (US), Exact Sciences' Cancerguard (US) and Freenome (US), Novigenix in Switzerland, and Singlera Genomics in China. Source: https://en.bioecon.ru/technology/multi-cancer-early-detection/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: IVDR 2017/746 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)] Multi-cancer early detection (MCED) screens asymptomatic, average-risk individuals from a single blood draw for molecular signals shared across dozens of cancer types simultaneously, aiming to catch cancer at an earlier, more treatable stage before symptoms or standard single-cancer screening would detect it — a population-screening use case distinct from the treatment-matched companion diagnostics covered elsewhere in this catalog. GRAIL's Galleri test reported full results from the NHS-Galleri trial at the 2026 ASCO Annual Meeting, demonstrating a substantial reduction in stage IV cancer diagnoses, increased stage I/II detection of deadly cancers, and a four-fold higher cancer detection rate; GRAIL also presented Pathfinder 2 results from more than 35,000 participants and has submitted an FDA premarket approval (PMA) application for Galleri. Exact Sciences launched Cancerguard, which it calls the first-of-its-kind multi-cancer early detection blood test. Freenome's SimpleScreen colorectal-cancer blood test met all primary and secondary endpoints with 85% sensitivity for CRC and 22% for advanced precancerous lesions, alongside separate multiomic blood-screening data for lung cancer. In Switzerland, Novigenix runs an AI-powered blood-transcriptomic platform with published results on early colorectal-cancer detection, recently securing funding to scale its precision-oncology platform. In China, Singlera Genomics develops multi-cancer early-screening panels including its ColonAiQ product. The key directions of multi-cancer early detection are: 1. **Cell-free DNA methylation screening (Cell-Free DNA Methylation):** methylation-pattern analysis of cell-free DNA to detect and localize a cancer signal across dozens of cancer types from one blood draw — GRAIL's Galleri. 2. **Multiomic blood screening (Multiomic Blood Screening):** combining genomic, proteomic and other molecular layers from blood to improve single- and multi-cancer detection sensitivity — Freenome, Exact Sciences' Cancerguard. 3. **Blood transcriptomic AI screening (Blood Transcriptomic Screening):** RNA expression signatures in blood analyzed with machine learning to flag early cancer signals — Novigenix. 4. **Regional MCED panels (Regional MCED Panels):** multi-cancer screening products developed and validated for a domestic population and regulatory pathway — Singlera Genomics. ### Sectoral value chain ``` [blood draw] ──> [cfDNA/multiomic/transcriptomic signal extraction] ──> [ML classifier & cancer-signal-origin prediction] │ (screening result & confirmatory workup) │ ▼ [population screening program adoption] <─── [regulatory approval & clinical validation] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Blood Draw** | a single venous blood sample collected from an asymptomatic, average-risk individual | **In:** screening participant.
**Out:** blood sample. | | **Signal Extraction** | cfDNA methylation, multiomic or transcriptomic profiling extracts the molecular signal from the blood sample | **In:** blood sample.
**Out:** molecular signal data. | | **ML Classifier & Origin Prediction** | a machine-learning classifier flags a cancer signal and predicts its likely tissue of origin | **In:** molecular signal data.
**Out:** cancer-signal-detected/not-detected call + predicted origin. | | **Screening Result & Confirmatory Workup** | a signal-detected result triggers diagnostic imaging/biopsy workup to confirm or rule out cancer | **In:** classifier result.
**Out:** confirmed diagnosis or ruled-out result. | | **Regulatory Approval & Validation** | large prospective trials (NHS-Galleri, Pathfinder 2) and FDA/EMA/NMPA review validate clinical utility | **In:** trial outcome data.
**Out:** approved/validated screening test. | | **Population Screening Adoption** | health systems and payers adopt the test into routine average-risk population screening programs | **In:** validated test, payer/health-system decision.
**Out:** population-scale screening deployment. | Cross-cutting technologies of the sector: - **Cell-free DNA methylation analysis (Cell-Free DNA Methylation):** cancer-specific methylation patterns in cell-free DNA distinguish tumor-derived signal from background and predict the cancer's tissue of origin, GRAIL's core Galleri technology. - **Multiomic integration (Multiomic Blood Screening):** combining multiple molecular data types (genomic, proteomic) from a single blood sample improves detection sensitivity beyond any single biomarker class, Freenome's core approach. - **AI-based transcriptomic classification (Blood Transcriptomic Screening):** machine-learning models trained on blood RNA expression signatures flag early cancer-associated immune and tissue response patterns, Novigenix's core technology. --- ## US The US anchors the deepest MCED platform bench, with large prospective trial results now driving regulatory submissions and payer conversations. ### Galleri, Cancerguard, SimpleScreen, FDA - **GRAIL:** reported full NHS-Galleri trial results at the 2026 ASCO Annual Meeting showing a substantial reduction in stage IV cancer diagnoses and a four-fold higher cancer detection rate, presented Pathfinder 2 results from more than 35,000 participants, and has submitted an FDA PMA application for Galleri. - **Exact Sciences:** launched Cancerguard, which the company calls the first-of-its-kind multi-cancer early detection blood test. - **Freenome:** its SimpleScreen colorectal-cancer blood test met all primary and secondary endpoints (85% sensitivity for CRC, 22% for advanced precancerous lesions), alongside separate multiomic lung-cancer screening data. - **FDA framework:** MCED tests currently reach the US market predominantly as laboratory-developed tests (LDTs) under CLIA, with GRAIL's Galleri PMA submission representing the category's push toward full FDA premarket approval. --- ## CN China develops domestic multi-cancer early-screening panels adapted to the local population and regulatory pathway, with Singlera Genomics among the active developers. ### Singlera Genomics, NMPA - **Singlera Genomics:** develops multi-cancer early-screening panels including its ColonAiQ product, part of China's growing early-cancer-detection testing base. - **NMPA framework:** multi-cancer screening tests in China require NMPA approval as in-vitro diagnostic products, validated against the domestic population's cancer-incidence profile. --- ## EU Switzerland anchors a European MCED entrant through Novigenix's AI-powered blood-transcriptomic screening platform. ### Novigenix, IVDR - **Novigenix:** runs an AI-powered blood-transcriptomic platform with published results on early colorectal-cancer detection, and recently secured funding (EUR 1.8 million) to scale its precision-oncology platform and spun out an AI-focused unit to accelerate its immune-intelligence technology. - **IVDR framework:** multi-cancer screening tests sold in the EU require conformity assessment and CE marking under the In Vitro Diagnostic Regulation (IVDR 2017/746), with clinical-utility evidence from large prospective trials increasingly central to that assessment. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **GRAIL** | 🇺🇸 USA | *Galleri MCED test* | cfDNA methylation, FDA PMA submitted | growth | | **Exact Sciences** | 🇺🇸 USA | *Cancerguard* | First-of-its-kind MCED blood test | commercial | | **Freenome** | 🇺🇸 USA | *SimpleScreen CRC / lung multiomic screen* | 85% CRC sensitivity, multiomic | growth | | **Singlera Genomics** | 🇨🇳 China | *ColonAiQ / multi-cancer panels* | Domestic early-screening panels | growth | | **Novigenix** | 🇨🇭 Switzerland | *AI blood-transcriptomic platform* | AI immune-intelligence screening | growth | --- ## Tech stack and innovations The stack converts a single blood draw into a multi-cancer signal by extracting a molecular layer (cfDNA methylation, multiomic markers, or transcriptomic RNA signatures) and classifying it with machine learning trained on large prospective screening cohorts. 1. **cfDNA methylation-based detection (Cell-Free DNA Methylation):** - GRAIL's Galleri analyzes methylation patterns across cell-free DNA fragments to detect a shared cancer signal spanning dozens of cancer types and predict the likely tissue of origin, validated in the NHS-Galleri and Pathfinder 2 trials. 2. **Multiomic blood-based screening (Multiomic Blood Screening):** - Freenome combines genomic and proteomic signal layers from a single blood draw, achieving 85% sensitivity for colorectal cancer in its SimpleScreen test while extending the same multiomic approach to lung-cancer screening. 3. **AI-powered blood transcriptomics (Blood Transcriptomic Screening):** - Novigenix applies machine learning to blood RNA expression signatures, identifying immune and tissue-response patterns associated with early-stage colorectal cancer. 4. **Domestic MCED panel development (Regional MCED Panels):** - Singlera Genomics builds multi-cancer screening panels (including ColonAiQ) validated against China's domestic population and regulatory requirements. --- ## Value chains and production pipelines ### Industrial pipeline of a multi-cancer early detection test (FDA LDT/PMA / EU IVDR 2017/746) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Blood draw │ ───> │ 2. Signal extraction │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Screening result & │ <─── │ 3. ML classifier & │ │ confirmatory workup │ │ origin prediction │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Regulatory approval & │ ───> │ 6. Population screening │ │ validation │ │ adoption │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Blood draw A single venous blood sample is collected from an asymptomatic, average-risk individual as part of a routine or opt-in screening visit, requiring no prior symptom or elevated-risk trigger. #### Stage 2: Signal extraction The molecular signal is extracted from the sample — cfDNA methylation patterns (GRAIL), combined genomic/proteomic multiomic markers (Freenome), or blood transcriptomic RNA expression (Novigenix) — depending on the platform's core technology. #### Stage 3: ML classifier and origin prediction A machine-learning classifier trained on large prospective cohorts (GRAIL's Pathfinder 2 exceeded 35,000 participants) determines whether a cancer signal is present and predicts the likely tissue of origin to guide follow-up. #### Stage 4: Screening result and confirmatory workup A signal-detected result triggers diagnostic imaging or biopsy workup targeted at the predicted cancer origin to confirm or rule out a diagnosis; a signal-not-detected result returns the individual to standard screening guidelines. #### Stage 5: Regulatory approval and validation Large prospective trials such as NHS-Galleri and FDA PMA review (for GRAIL) or IVDR conformity assessment (for Novigenix) establish the clinical-utility evidence base required before a test is adopted into standard care. #### Stage 6: Population screening adoption Health systems and payers adopt the validated test into routine average-risk population-screening programs, the stage the NHS-Galleri trial's stage-IV-reduction and detection-rate results are specifically designed to support.